Blake Borgeson Sells 8,885 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Rating) Director Blake Borgeson sold 8,885 shares of the company’s stock in a transaction that occurred on Tuesday, January 10th. The shares were sold at an average price of $7.69, for a total value of $68,325.65. Following the sale, the director now directly owns 7,620,712 shares in the company, valued at $58,603,275.28. The transaction was disclosed in a filing with the SEC, which is available at this link.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, December 27th, Blake Borgeson sold 8,885 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $7.25, for a total value of $64,416.25.
• On Tuesday, December 13th, Blake Borgeson sold 8,885 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.96, for a total value of $79,609.60.
• On Tuesday, November 29th, Blake Borgeson sold 8,885 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.75, for a total value of $77,743.75.
• On Wednesday, November 16th, Blake Borgeson sold 17,770 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $11.12, for a total value of $197,602.40.

Recursion Pharmaceuticals Price Performance

Shares of RXRX opened at $8.70 on Friday. The company has a market cap of $1.65 billion, a P/E ratio of -6.04 and a beta of -0.47. The stock has a fifty day moving average price of $8.88 and a 200 day moving average price of $9.75. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.92 and a 12 month high of $14.22.

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Rating) last released its quarterly earnings results on Tuesday, November 8th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.01. Recursion Pharmaceuticals had a negative return on equity of 53.04% and a negative net margin of 860.34%. The company had revenue of $13.16 million during the quarter, compared to analysts’ expectations of $6.43 million. As a group, research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.38 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of RXRX. Swiss National Bank grew its stake in shares of Recursion Pharmaceuticals by 7.6% in the first quarter. Swiss National Bank now owns 94,300 shares of the company’s stock worth $675,000 after purchasing an additional 6,700 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Recursion Pharmaceuticals by 1.7% in the first quarter. Bank of New York Mellon Corp now owns 373,700 shares of the company’s stock worth $2,676,000 after purchasing an additional 6,294 shares in the last quarter. MetLife Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 55.4% in the first quarter. MetLife Investment Management LLC now owns 64,035 shares of the company’s stock worth $458,000 after purchasing an additional 22,833 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Recursion Pharmaceuticals by 4.0% in the first quarter. Rhumbline Advisers now owns 123,892 shares of the company’s stock worth $887,000 after purchasing an additional 4,818 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Recursion Pharmaceuticals by 8.1% in the first quarter. Vanguard Group Inc. now owns 6,611,377 shares of the company’s stock worth $47,338,000 after purchasing an additional 497,504 shares in the last quarter. Institutional investors own 63.62% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently commented on RXRX shares. SVB Leerink lowered their price objective on Recursion Pharmaceuticals from $10.00 to $9.00 and set a “market perform” rating for the company in a research note on Tuesday, October 25th. The Goldman Sachs Group upped their price objective on Recursion Pharmaceuticals from $8.00 to $9.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 9th.

Recursion Pharmaceuticals Company Profile

(Get Rating)

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis.